

S2 File. Linear regression analyses between disease activity and body composition in early arthritis patients, stratified for gender and corrected for age and smoking status.

	FMI	Percentages of fat distributed to the trunk	Android to gynoid fat mass ratio	ALMI
	B (CI) and p-value	B (CI) and p-value	B (CI) and p-value	B (CI) and p-value
<i>Females, n=220</i>				
ESR in mm/hour (median, IQR)	0.04 (0.00-0.07) 0.028	0.01 (-0.03-0.04) 0.797	<0.01 (0.00-0.00) 0.861	<0.01 (0.00-0.01) 0.387
DAS28 (mean, SD)	0.33 (-0.17-0.83) 0.194	-0.39 (-0.98-0.20) 0.190	-0.01 (-0.02-0.01) 0.343	-0.01 (-0.10-0.081) 0.869
SJC38 (median, IQR)	-0.09 (-0.20-0.01) 0.089	-0.13 (-0.26- -0.01) 0.040	<0.01 (-0.01-0.00) 0.030	-0.01 (-0.03-0.01) 0.195
TJC38 (median, IQR)	0.06 (-0.03-0.15) 0.204	-0.03 (-0.14-0.07) 0.534	<0.01 (0.00-0.00) 0.894	<0.01 (-0.01-0.05) 0.403
RF positive (n,%)	0.44 (0.99-1.87) 0.546	0.43 (-1.27-2.13) 0.616	0.02 (-0.02-0.06) 0.400	0.03 (-0.22-0.28) 0.812
ACPA positive (n,%)	-0.04 (-1.49-1.42) 0.963	0.89 (-0.83-2.61) 0.310	0.02 (-0.02-0.06) 0.389	-0.07 (-0.33-0.19) 0.238
HAQ-DI (median, IQR)	0.99 (-0.01-1.98) 0.052	-0.92 (-2.08-0.24) 0.120	-0.01 (-0.04-0.02) 0.387	0.04 (-0.14-0.22) 0.654
Symptom duration, months (median, IQR)	0.01 (0.00-0.02) 0.068	0.01 (0.00-0.03) 0.020	<0.01 (0.00-0.00) 0.478	<0.01 (0.00-0.00) 0.068
<i>Males, n=97</i>				
ESR in mm/hour (median, IQR)	<0.01 (-0.04-0.04) 0.969	-0.04 (-0.09-0.02) 0.173	<0.01 (0.00-0.00) 0.615	<0.01 (-0.01-0.01) 0.543
DAS28 (mean, SD)	0.48 (-0.15-1.10) 0.132	-0.10 (-1.02-0.83) 0.834	<0.01 (-0.03-0.03) 0.935	0.03 (-0.13-0.19) 0.694
SJC38 (median, IQR)	0.05 (-0.06-0.17) 0.365	<0.01 (-0.17-0.17) 0.998	<0.01 (-0.01-0.00) 0.486	0.02 (-0.01-0.05) 0.189
TJC38 (median, IQR)	0.10 (0.00-0.21) 0.204	-0.02 (-0.17-0.14) 0.844	<0.01 (-0.01-0.00) 0.655	0.02 (-0.01-0.05) 0.134
RF positive (n,%)	1.04 (-0.79-2.88) 0.261	-2.24 (-4.90-0.43) 0.098	-0.04 (-0.12-0.04) 0.352	0.36 (-0.11-0.82) 0.132
ACPA positive (n,%)	-0.20 (-2.06-1.65) 0.829	-2.04 (-4.72-0.64) 0.135	-0.07 (-0.15-0.02) 0.109	-0.16 (-0.63-0.32) 0.511
HAQ-DI (median, IQR)	0.52 (-0.76-1.79) 0.422	0.18 (-1.62-1.98) 0.841	0.02 (-0.03-0.08) 0.443	0.05 (-0.27-0.37) 0.761
Symptom duration, months (median, IQR)	0.04 (0.00-0.07) 0.044	0.01 (-0.04-0.06) 0.744	<0.01 (0.00-0.00) 0.478	0.01 (0.00-0.02) 0.024

ACPA: anti-citrullinated protein antibody, ALMI: appendicular lean mass index, B: beta (1 point increase in parameters of disease activity is X change in FMI, percentages of fat distributed to the trunk, android to gynoid fat mass ratio or LMI), CI: confidence interval, DAS28: disease activity score of 28 joints, ESR: erythrocyte sedimentation rate, FMI: fat mass index, HAQ-DI: health assessment questionnaire disability index, mm/hour: millimetre/hour, n:number, RF: rheumatoid factor, SJC38: swollen joint count of 38 joints, TJC38: tender joint count of 38 joints

*significant results at the 0.05 false discovery rate for 64 tests.